Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.54 |
| ▸ | FDPS | P14324 | 1/20 | 0.49 |
| ▸ | TBXAS1 | P24557 | 12/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1915970 | 0.82 | CPA3 (0.56) | CYP1A2 | |
| SCHEMBL27581965 | 0.80 | NAPRT (0.59) | NAPRTFDPSTBXAS1KDM4ELMNA | |
| SCHEMBL2028393 | 0.78 | DPP4 (0.57) | NAPRTFDPSTBXAS1KDM4ELMNA | |
| SCHEMBL29478409 | 0.78 | DPP4 (0.57) | NAPRTFDPSTBXAS1KDM4ELMNA | |
| SCHEMBL20366127 | 0.78 | CPA1 (0.67) | NAPRTFDPSTBXAS1KDM4ELMNA | |
| SCHEMBL2568949 | 0.78 | KDM4E (0.54) | NAPRTFDPSTBXAS1KDM4ELMNA | |
| SCHEMBL29478423 | 0.78 | DPP4 (0.57) | NAPRTFDPSTBXAS1KDM4ELMNA | |
| SCHEMBL2034613 | 0.78 | DPP4 (0.57) | NAPRTFDPSTBXAS1KDM4ELMNA | |
| SCHEMBL2028392 | 0.78 | DPP4 (0.57) | NAPRTFDPSTBXAS1KDM4ELMNA | |
| SCHEMBL6885074 | 0.75 | KDM4E (0.62) | NAPRTFDPSTBXAS1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113166114-B | Cyclic tetramer compounds as inhibitors of proprotein convertase subtilisin/KEXIN type 9 (PCSK 9) for the treatment of metabolic disorders | 诺华股份有限公司 | 2025-01-03 | — | — | CN | disclosed |